Abstract
Background The effectiveness of MAPK pathway inhibitors (MAPKi) used to treat patients with BRAF-mutant melanoma is limited by a range of resistance m......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
